ARS | Publication request: Protein Hydrolysates from Beta-Conglycinin Enriched Soybean Genotypes Inhibit Lipid Accumulation and Inflammation in Vitro

Submitted to: Molecular Nutrition and Food Research
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: December 17, 2008
Publication Date: July 31, 2009
Citation: Martinez-Villaluenga, C., Dia, V.P., Berhow, M.A., Bringe, N.A., Gonzalez De Mejia, E. 2009. Protein Hydrolysates from Beta-Conglycinin Enriched Soybean Genotypes Inhibit Lipid Accumulation and Inflammation in Vitro. Molecular Nutrition and Food Research. 53:1007-1018.

Interpretive Summary: Obesity is a worldwide health concern and a well recognized predictor of premature mortality associated with a state of chronic inflammation. Soy proteins from different genotypes were modified by a series of enzymatic digestions to form soy protein hydrolysates, then evaluated for their biologically functional components, and evaluated for their anti-inflammatory activity in cell culture models. It was determined that soy hydrolysates that were rich in beta-conglycinin slowed lipid accumulation in the model cell lines, and slowed or stopped the initiation of inflammatory pathways. This shows that characterized soy protein hydrolysates can be used as a food additive in diets to control obesity.

Technical Abstract: Obesity is a worldwide health concern and a well recognized predictor of premature mortality associated with a state of chronic inflammation. The objective was to evaluate the effect of soy protein hydrolysates (SPH) produced from different soybean genotypes by alcalase (SAH) or simulated gastrointestinal digestion (SGIH) on lipid accumulation in 3T3-L1 adipocytes. The anti-inflammatory effect of SPH produced by alcalase on LPS-induced macrophage RAW 264.7 cell line was also investigated. SAH (100 uM) derived from soybean enriched in beta-conglycinin (BC) (up to 47% total protein) decreased lipid accumulation (33-37% inhibition) through downregulation of gene expression of lipoprotein lipase (LPL) and fatty acid synthase (FAS). SGIH (100 uM) inhibited lipid accumulation to a lesser extent (8-14% inhibition) through inhibition of LPL gene expression. SAH (5 uM) decreased the production of nitric oxide (NO) (18-35%) and prostaglandin E2 (PGE2) (47-71%) and the expression of inducible nitric oxide synthase (iNOS) (31-53%) and cycloxygenase-2 (COX-2) (30-52%). This is the first investigation showing that soy hydrolysates inhibit LPS-induced iNOS/NO and COX-2/PGE2 pathways in macrophages. Soybeans enriched in BCs can provide hydrolysates that limit fat accumulation in fat cells and inflammatory pathways in vitro and, therefore, warrant further studies as a healthful food.